NCT00721539 · REGISTRY CONDITION SEARCH

Assessing the da Vinci® Robotic Surgical System for Surgery of the Upper Aerodigestive Tract

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: NA
Status at capture: TERMINATED
Registry last update: 2016-11-03

To assess the use of the da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) in transoral surgeries in patients with benign and malignant lesions of the oral cavity and laryngopharynx.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Complication Rate (Intraoperative and Postoperative)

→

outcome · POSTED

Feasibility Defined as Ability to Perform the Planned Diagnostic or Therapeutic Procedure

→

outcome · POSTED

Average Blood Loss

→

outcome · POSTED

Average Operative Time

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Patient or volunteer is 18 years of age or older * Patients must have indication for diagnosis and/or therapy of diseases of the oropharynx, hypopharynx, and/or larynx. Exclusion Criteria: * unexplained fever and/or untreated * active infection * pregnancy * anatomic parameters which preclude transoral surgery, such as: 1. trismus 2. limited range of neck motion 3. poor dentition 4. redundant hypopharyngeal or supraglottic tissue which would prevent adequate visualization of the tumor * participation in a research protocol which precludes participation in other protocols
healthy Volunteers: false
minimum Age: 18 Years
sex: MALE
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Pilot study; single arm - use of da Vinci Surgical Robot Platform to access neoplastic disease of the upper aerodigestive tract.
intervention Names
Device: da Vinci Surgical Robot Platform
Procedure: Transoral Robotic Surgery
label
Transoral Robotic Surgery
type
OTHER

interventions

arm Group Labels
Transoral Robotic Surgery
description
daVinci Surgical Robot Platform is a surgical device that enhances transoral access to the upper aerodigestive tract through miniaturization of endoscopes and micromanipulators that can be introduced through the mouth.
name
da Vinci Surgical Robot Platform
type
DEVICE
arm Group Labels
Transoral Robotic Surgery
description
Eligible patients will undergo transoral treatment of neoplastic disease of the upper aerodigestive tract using the daVinci Surgical Robot Platform as opposed to traditional (TOL - transoral laser; TEC - transoral electrocautery) methods.
name
Transoral Robotic Surgery
type
PROCEDURE

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

HEALTH_SERVICES_RESEARCH

Enrollment

count: 9
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Complications encountered intraoperatively or up to six weeks postoperatively. This would include injury to patient, hemorrhage, lacerations, and readmission following surgery.
measure
Overall Complication Rate (Intraoperative and Postoperative)
time Frame
Six weeks

secondary Outcomes

measure
Feasibility Defined as Ability to Perform the Planned Diagnostic or Therapeutic Procedure
time Frame
Six weeks
description
Blood lost during procedure
measure
Average Blood Loss
time Frame
Duration of procedure up to two hours
description
Average operative time in minutes
measure
Average Operative Time
time Frame
Up to four hours (240 minutes)

Full study description

brief Summary: To assess the use of the da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) in transoral surgeries in patients with benign and malignant lesions of the oral cavity and laryngopharynx.
detailed Description: In the past two decades the interest in minimally invasive techniques for transoral treatment of head and neck benign and malignant lesions has been growing due to the decreased morbidity of transoral approaches, and some surgeons have been moving away from traditional open resections. Transoral resection of neoplasms of the upper aerodigestive, by its minimally invasive nature, may afford a shorter hospitalization and recovery time for patients when compared to those patients who undergo traditional "open" surgery. In surgery of the oropharynx, hypopharynx, and larynx, transoral endoscopic surgery can provide similar outcomes in terms of local control of disease when compared to open procedures, while improving time to restoration of oral intake and shortening time to tracheostomy decannulation. Therefore, in select patients, a transoral surgical approach may afford clear advantages over traditional open approaches. Current techniques, however, are limited by the inability to attain direct line of site exposure of the lesion. Use of robot-assisted technology as a means to overcome surgical limitations, to provide surgeons with improved dexterity and precision, and to couple advanced imaging techniques with three-dimensional depth perception, may allow for the completion of transoral surgical approaches in patients for whom conventional technology has been suboptimal. The da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) is FDA-approved for use in a variety of laparoscopic, thoracoscopic, cardiac, and urologic surgical procedures. This protocol will assess the use of the da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) in transoral surgeries in patients with benign and malignant lesions of the oral cavity and laryngopharynx. Traditional endoscopic removal of tumors of the oropharynx and laryngopharynx is usually preferred to traditional open resection because of the decrease in morbidity and improved functional outcomes experienced by patients. The limiting step in these procedures has been exposure of, visualization of, and access to candidate tumors. The da Vinci surgical system offers the possibility of significant improvements in exposure, visualization and access to these candidate tumors with no added risk to patients. Overall this may significantly increase the number of patients who are candidates for endoscopic surgery. Alternative procedures will include traditional open surgical removal of tumors as well as traditional endoscopic removal of tumors using the microscope and CO2 laser. Open surgical approaches are reserved for patients who have large tumors unsuitable for endoscopic removal or in whom endoscopic visualization of the tumor is inadequate or impossible. The da Vinci surgical system would offer improved visualization of tumors that might otherwise be inaccessible to a traditional endoscopic approach. Candidate patients will present with a neoplasm of the oropharynx, hypopharynx or larynx. Those patients assessed preoperatively to be candidates for transoral surgery (eg, Mallampati class I or II, normal range of neck motion, no trismus) will undergo surgery via a transoral approach to resect the tumor. This will require general anesthesia and may require postoperative hospitalization. If the tumor can be accessed, resection will proceed using the da Vinci robot. In whom the tumor cannot be accessed, resection will proceed via the conventional open approach. Pre and postoperative care will not be affected by this protocol, as it deals strictly with the manner in which the tumor is removed. Postoperative care and visits are standardized as to the nature of the tumor (eg, malignant tumors usually require follow-up visits every four to six weeks to monitor for tumor recurrence). Complications, blood loss, operative time, length of hospitalization, time to resumption of oral intake, time to decannulation, and overall local control rates will be assessed in the postoperative period.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-8c13b19d5fd1fe55fa8e
requested nct id
NCT00721539
primary nct id
NCT00721539
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hypopharyngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
payload sha256
35fd2c7085215b5ea30401a4dc88fd7abb19426a4ab5bb4aef6da603f62ea68d
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-8c13b19d5fd1fe55fa8e
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00721539
occurrences
context exact
NCT00721539
end
11
exact text
NCT00721539
start
0
offset unit
unicode_code_points
query cond
Hypopharyngeal Cancer
query disease state id
ds-hypopharyngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
source file sha256
cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
source json pointer
/studies/88/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
73c7b3be81282dec6734385f117c10c890b5405e4c4df196aade904508c1a83c
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hypopharyngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-bc799fe16f16f8584111
requested nct id
NCT00721539
primary nct id
NCT00721539
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
payload sha256
4cb6a5e43e06d518c54c76cc5c09134deabd13ab61d4ff24d23d61f2458e4b60
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-bc799fe16f16f8584111
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00721539
occurrences
context exact
NCT00721539
end
11
exact text
NCT00721539
start
0
offset unit
unicode_code_points
query cond
Laryngeal Cancer
query disease state id
ds-laryngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
source json pointer
/studies/123/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
73c7b3be81282dec6734385f117c10c890b5405e4c4df196aade904508c1a83c
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice